Email this article 
Post a Comment Evaluation of the effectiveness of transarterial chemoembolization irinotecan-loaded with drug-saturable microspheres for the treatment of patients with neuroendocrine tumors with liver metastases
- Authors: Zvezdkina E.A.1, Kedrova A.G.2,3,4, Lebedev D.P.2, Krasilnicov S.E.4, Krestyaninov O.V.4, Greyan T.A.2,3, Panchenkov D.N.5, Stepanova Y.A.6
-
Affiliations:
- The Skobelkin Research and Practical Centre for Laser Medicine
- Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency
- Academy of Postgraduate Education Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency
- E.N. Meshalkin National Medical Research Center
- Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
- A.V. Vishnevsky National Medical Research Center of Surgery
- Issue: Vol 13, No 4 (2022)
- Pages: 27-37
- Section: Original Study Articles
- URL: https://journals.rcsi.science/clinpractice/article/view/144167
- DOI: https://doi.org/10.17816/clinpract115017
- ID: 144167
Cite item
Abstract
Background: Since 2021, transarterial chemoembolization of the hepatic arteries (TACE) has been included in the recommendations of professional communities for the treatment of metastases of neuroendocrine liver tumors (NEO). However, the heterogeneity of both this group of patients and types of chemoembolization with a limited range of cytostatics used in the treatment makes it difficult to analyze the data and introduce the method into the combination therapy regimens.
Aim: to study the effectiveness of transarterial chemoembolization with irinotecan-loaded drug-saturable microspheres for the treatment of patients with neuroendocrine tumors with liver metastases.
Methods: A retrospective, observational, uncontrolled study of 34 patients with liver metastases from neuroendocrine cancer who underwent 52 TACE with irinotecan-loaded drug-saturable microspheres. Group 1 consisted of 15 patients who already had liver metastases at the time of the primary focus detection, group 2 included 19 patients with liver metastases having appeared some time after the detection of the primary focus. To plan and evaluate the effectiveness of chemoembolization, computed tomography and magnetic resonance imaging were used every 10–15 weeks during the systemic treatment. All the patients received systemic NEO therapy before and after the embolization.
Results: An increase in the progression-free time from 101 [57; 120] and 145 [89; 263] days after chemotherapy up to 300 [134; 344] and 304 [240; 342] days after TACE in groups 1 and 2, respectively, with no difference between the groups (p=0.31 and p=0.57, respectively). We did not find a linear relationship between the doubling time of the tumor and the change in the volume of the tumor lesion (R2=0.1085 and R2=0.0265 in groups 1 and 2). When comparing the intragroup scores, there was a statistically significant difference (p=0.009, p=0.046) in the tumor volume reduction and progression-free time between the patients who underwent TACE immediately and those who underwent TACE after chemotherapy. The diagnostic and angiographic images of liver metastases varied within the same organ and depended on the size of metastases. There were no adverse events after TACE.
Conclusions: TACE with irinotecan-loaded drug-saturable microspheres is an effective method for the treatment of liver metastases of neuroendocrine cancer, allowing one to increase the time without progression.
Full Text
##article.viewOnOriginalSite##About the authors
Elena A. Zvezdkina
The Skobelkin Research and Practical Centre for Laser Medicine
Author for correspondence.
Email: zvezdkina@yandex.ru
ORCID iD: 0000-0002-0277-9455
SPIN-code: 8428-4518
MD, PhD, research associate
Russian Federation, 40, Studentcheskaya street, Moscow, 121165Anna G. Kedrova
Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency; Academy of Postgraduate Education Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency; E.N. Meshalkin National Medical Research Center
Email: kedrova.anna@gmail.com
ORCID iD: 0000-0003-1031-9376
SPIN-code: 3184-9760
MD, PhD, professor
Russian Federation, Moscow; Moscow; NovosibirskDmitry P. Lebedev
Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency
Email: lebedevdp@gmail.com
ORCID iD: 0000-0003-1551-3127
SPIN-code: 4770-5722
doctor for X-ray endovascular diagnostics and treatment
Russian Federation, MoscowSergey E. Krasilnicov
E.N. Meshalkin National Medical Research Center
Email: krasilnikov_s@meshalkin.ru
ORCID iD: 0000-0001-8366-6083
Director of the Institute of Oncology and Neurosurgery
Russian Federation, NovosibirskOleg V. Krestyaninov
E.N. Meshalkin National Medical Research Center
Email: o_krestyaninov@meshalkin.ru
ORCID iD: 0000-0001-5214-8996
Head of the Research Department of Endovascular Surgery of the Institute of Oncology and Neurosurgery
Russian Federation, NovosibirskTatevic A. Greyan
Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency; Academy of Postgraduate Education Federal Scientific and Clinical Center for Specialized Medical Assistance and Medical Technologies of the Federal Medical Biological Agency
Email: tatev111@gmail.com
ORCID iD: 0000-0003-4118-3002
SPIN-code: 6952-4709
Oncologist of the oncology department, Senior Lecturer of the Department of Obstetrics and Gynecology
Russian Federation, Moscow; MoscowDmitry N. Panchenkov
Moscow State University of Medicine and Dentistry named after A.I. Evdokimov
Email: dnpanchenkov@mail.ru
ORCID iD: 0000-0001-8539-4392
SPIN-code: 4316-4651
Doctor of Medical Sciences, Professor, Head of the Laboratory of Minimally Invasive Surgery
Russian Federation, MoscowYulia A. Stepanova
A.V. Vishnevsky National Medical Research Center of Surgery
Email: stepanovaua@mail.ru
ORCID iD: 0000-0002-2348-4963
SPIN-code: 1288-6141
Doctor of Medical Sciences, Senior Researcher, Department of Radiation Methods of Diagnosis and Treatment
Russian Federation, MoscowReferences
- Modlin IM, Lye KD, Kidd MA. 5-Decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97(4):934–959. doi: 10.1002/cncr.11105
- Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95(2):157–176. doi: 10.1159/000335597
- Lucatelli P, Burrel M, Guiu B, et al. CIRSE standards of practice on hepatic transarterial chemoembolisation. Cardiovasc Intervent Radiol. 2021;44(12):1851–1867 doi: 10.1007/s00270-021-02968-1
- De Baere T, Plotkin S, Yu R, et al. An in vitro evaluation of four types of drug-eluting microspheres loaded with doxorubicin. J Vasc Interv Radiol. 2016;27(9):1425–1431. doi: 10.1016/j.jvir.2016.05.015
- Kennoki N, Saguchi T, Sano T, et al. Long-term histopathologic follow-up of a spherical embolic agent; observation of the transvascular migration of HepaSphere TM. BJR Case Rep. 2019;5(1):20180066. doi: 10.1259/bjrcr.20180066
- Fjallskog ML, Janson ET, Falkmer UG, et al. Treatment with combined streptozotocin and liposomal doxorubicin in metastatic endocrine pancreatic tumors. Neuroendocrinology. 2008; 88(1):53–58. doi: 10.1159/000117575
- Schwartz M. A biomathematical approach to clinical tumor growth. Cancer. 1961;14:1272–1294. doi: 10.1002/1097- 0142(196111/12)14:6<1272::aid-cncr2820140618>3.0.co;2-h
- Рак печени (гепатоцеллюлярный). Клинические рекомендации. Ассоциация онкологов России; Междисциплинарное общество специалистов по опухолям печени; Российское общество клинической онкологии; Российское общество рентгенологов и радиологов; 2022. [Liver cancer (hepatocellular). Clinical recommendations. Association of Oncologists of Russia; Interdisciplinary Society of Specialists in Liver Tumors; Russian Society of Clinical Oncology; Russian Society of Radiologists and Radiologists; 2022. (In Russ).]
- Орел Н.Ф., Артамонова Е.В., Горбунова В.А., и др. Практические рекомендации по лекарственному лечению нейроэндокринных неоплазий желудочно-кишечного тракта и поджелудочной железы // Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018. Т. 8, № 3. С. 430–439. [Orel NF, Artamonova EV, Gorbunova VA, et al. Practical recommendations for the drug treatment of neuroendocrine neoplasia of the gastrointestinal tract and pancreas. Malignant tumors: Practical recommendations RUSSCO #3s2. 2018;8(3):430–439. (In Russ).]
- Do Minh D, Chapiro J, Gorodetski B, et al. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model. Eur Radiol. 2017;27(12):4995–5005. doi: 10.1007/s00330-017-4856-2
- Da Dong X, Carr BI. Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol. 2011;28(1): 286–290. doi: 10.1007/s12032-010-9750-6
- Wáng YJ, De Baere T, Idée JM, Ballet S. Transcatheter embolization therapy in liver cancer: An update of clinical evidences. Chin J Cancer Res. 2015;27(2):96–121. doi: 10.3978/j.issn.1000-9604.2015.03.03
- Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420. doi: 10.1158/1078-0432.CCR-09-1624
- Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet Oncology. 2017;18(3):143–152. doi: 10.1016/S1470-2045(17)30074-8
Supplementary files
